Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.
about
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerCIViC databaseHeterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsNew developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?Mechanisms of resistance to EGFR-targeted drugs: lung cancerGeneration of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.Resisting Resistance: Targeted Therapies in Lung Cancer.Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity?The significance of programmed cell death ligand 1 expression in resected lung adenocarcinomaOvercoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer.Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First LineMolecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literatureMolecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report.Analysis of Cysteine Redox Post-Translational Modifications in Cell Biology and Drug Pharmacology.Understanding and targeting resistance mechanisms in NSCLC.Circulating DNA in EGFR-mutated lung cancer.Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study.Heterogeneity-based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report.An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance.Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.
P2860
Q26741998-93B0E920-C493-4DA1-BF48-0403A449B9CCQ26748851-40E3E968-D72B-4E8D-B672-5D9761213B0DQ27612411-F090FA1D-8C64-49FC-ACBE-20DCC78D2346Q27853391-7BD60645-3D03-4F11-9313-D3966DC7AA5FQ28069708-973E59A6-58D2-4FF7-9B11-1DE768B88337Q28075511-E798D9C2-FD47-4B8F-B5AD-2CB5AAD83E48Q28077415-E27E965F-6669-4FEB-AA95-09DEB8AB214AQ33829488-1EE96FB7-8DDD-4976-9EE5-2D6EA1DA8AF6Q34550460-2AFF99E1-EE55-4391-8F97-B419C5DF9073Q36586155-8CA30677-6C3C-4E83-B7CC-4F2455C4AB0CQ37388238-FD8D674F-5D8C-4982-A8AE-5A0F16896199Q37637905-241C2B2B-A4E4-410A-A94B-D6E91F2E1A50Q37666880-1F1C324C-F9E0-4B99-8DC8-161F67995911Q37694116-0492E54F-3E41-428E-A8DD-37823F91A2D4Q37725446-BA67BDC3-0B46-48C0-830C-D5B2D0A06F22Q38682189-517EB257-1CA1-4991-A1AB-A2EB07F3E7E3Q38721555-A3CF90A7-A9BA-4B90-B885-BDB22603F418Q38756349-1495BB6F-FF4C-42E7-9EE2-7A1396CDC641Q38766913-1EB46016-AE75-4073-8D69-3F2C6FD8BABFQ38838227-7C50AD73-0F65-4B86-A0F5-C245CEE6ABF5Q38988061-A565007E-1A31-47E8-82BC-F1F35B099C7DQ38991958-81E3C01A-0C8F-4762-9587-B4F4A3F7994BQ39114552-6FF08140-2183-44E5-956D-AF39D97AA7A0Q39172297-0BD73A3F-2261-40C4-8B89-024D8FDFDE7BQ40386800-4E2A3132-94E0-4313-AD76-3AB1DC085EFBQ41189462-BEA96658-F488-4C4C-BA34-1E7447498B30Q41547342-95AE8538-CA5B-41E2-A408-B41C12583B46Q41636404-DFE35F02-CCD7-4EA0-BCC2-6B82D20EFD68Q42363020-717CFB0A-1CC3-4A05-94FB-8D57529C4D99Q46424421-843326A3-037B-4BED-AC2E-53FC198E0DD3Q46915997-24805DEE-43C7-4DA1-A83C-4828C72F6AA1Q46917029-09C5F3CB-2DA1-4D4A-84B0-9AFB84DF121DQ47139649-FE46DF36-B7A7-4A14-9986-35603698BE33Q47146662-99308BDF-16FB-42C5-AE12-831EF9E53E6FQ47155456-474ABD45-0B38-4300-86A4-8EC954C330ADQ48091584-DF0BF3A5-C43D-43E9-87EC-74FDC0DD2BE6Q49667322-0BD05245-0127-44DB-859C-1A6B1C8CA4FAQ49887989-EF87452A-BB72-4F15-A964-4D95055CD2EEQ52597593-4B005F88-CD8B-451E-85DC-BCE864F3EB82Q53394177-E8573CE3-AE41-48C0-A21E-2AFDDEDD69C8
P2860
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Acquired Resistance of EGFR-Mu ...... e EGFR Tyrosine Kinase Domain.
@ast
Acquired Resistance of EGFR-Mu ...... e EGFR Tyrosine Kinase Domain.
@en
Acquired Resistance of EGFR-Mu ...... e EGFR Tyrosine Kinase Domain.
@nl
type
label
Acquired Resistance of EGFR-Mu ...... e EGFR Tyrosine Kinase Domain.
@ast
Acquired Resistance of EGFR-Mu ...... e EGFR Tyrosine Kinase Domain.
@en
Acquired Resistance of EGFR-Mu ...... e EGFR Tyrosine Kinase Domain.
@nl
altLabel
Acquired Resistance of EGFR- Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor
@en
prefLabel
Acquired Resistance of EGFR-Mu ...... e EGFR Tyrosine Kinase Domain.
@ast
Acquired Resistance of EGFR-Mu ...... e EGFR Tyrosine Kinase Domain.
@en
Acquired Resistance of EGFR-Mu ...... e EGFR Tyrosine Kinase Domain.
@nl
P2093
P2860
P3181
P1433
P1476
Acquired Resistance of EGFR-Mu ...... e EGFR Tyrosine Kinase Domain.
@en
P2093
Alexander E Drilon
Gregory J Riely
Helena A Yu
Laetitia Borsu
Maria E Arcila
Shaozhou K Tian
P2860
P356
10.1001/JAMAONCOL.2015.1066
P50
P577
2015-10-01T00:00:00Z